SCHEMBL171052

SCHEMBL171052

COC(=O)c1ccsc1C

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.53
SMN1; SMN2 Q16637 2/20 0.53
MEN1 O00255 1/20 0.53
KDM4E B2RXH2 3/20 0.50
POLB P06746 2/20 0.46
ATM Q13315 1/20 0.46
NPC1 O15118 2/20 0.45
RAB9A P51151 1/20 0.45
CNR2 P34972 1/20 0.44
NAMPT P43490 1/20 0.44
LMNA P02545 1/20 0.44
TSHR P16473 1/20 0.44
HPGD P15428 1/20 0.44
TDP1 Q9NUW8 2/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
ALDH1A1 P00352 2/20 0.42
CFTR P13569 1/20 0.42
HSD17B10 Q99714 1/20 0.42
ALOX12 P18054 1/20 0.42
MAPK10 P53779 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1844052 0.80 TSHR (0.57) KMT2AMEN1KDM4EPOLBNPC1
SCHEMBL70575 0.79 KMT2A (0.56) KMT2ASMN1; SMN2MEN1KDM4EPOLB
SCHEMBL163274 0.79 KMT2A (0.53) KMT2ASMN1; SMN2MEN1KDM4EPOLB
SCHEMBL25412667 0.78 NAMPT (0.45) KMT2ASMN1; SMN2MEN1KDM4EPOLB
SCHEMBL4016696 0.78 KMT2A (0.51) KMT2ASMN1; SMN2MEN1KDM4EPOLB
SCHEMBL19439589 0.78 KMT2A (0.51) KMT2ASMN1; SMN2MEN1KDM4EPOLB
SCHEMBL1450859 0.78 KMT2A (0.51) KMT2ASMN1; SMN2MEN1KDM4EPOLB
SCHEMBL13895781 0.78 KMT2A (0.51) KMT2ASMN1; SMN2MEN1KDM4EPOLB
SCHEMBL190088 0.78 KMT2A (0.59) KMT2ASMN1; SMN2MEN1KDM4EPOLB
SCHEMBL15111367 0.78 KMT2A (0.51) KMT2ASMN1; SMN2MEN1KDM4EPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 136 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260146037-A1 PEPTIDYL NITRILE COMPOUND AND USE THEREOF SHANGHAI YIDIAN PHARMACEUTICAL TECHNOLOGY DEVELOPMENT CO., LTD (CN) 2026-05-28 US disclosed
US-20260008780-A1 SUBSTITUTED 3,4-DIHYDROISOQUINOLIN-1(2H)-ONE DERIVATIVES AND RELATED USES NODTHERA LTD (GB) 2026-01-08 US disclosed
EP-4667054-A2 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY Novartis AG (CH) 2025-12-24 EP disclosed
EP-3880660-B1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY NOVARTIS AG (CH) 2025-07-02 EP disclosed
WO-2025137158-A1 DERIVATIVES OF ([1,2,4]TRIAZOLO[5,1-A]ISOQUINOLINE-5-CARBONYL)GLYCINATE AS PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2025-06-26 WO disclosed
CN-119859155-A Tri-fused ring derivative inhibitor, preparation method and application thereof 江苏豪森药业集团有限公司 2025-04-22 CN disclosed
EP-4536350-A1 SUBSTITUTED 3,4-DIHYDROISOQUINOLIN-1(2H)-ONE DERIVATIVES AND RELATED USES Nodthera Limited (GB) 2025-04-16 EP disclosed
CN-113166065-B Compounds and compositions for treating disorders associated with NLRP activity 诺华股份有限公司 2025-04-15 CN disclosed
US-20250109140-A1 5-[5-(PIPERIDIN-4-YL)THIENO[3,2-C]PYRAZOL-2-YL]INDAZOLE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR SPLICING NUCLEIC ACIDS AND FOR THE TREATMENT OF PROLIFERATIVE DISEASES REMIX THERAPUTICS INC (US) 2025-04-03 US disclosed
US-20250101011-A1 PEPTIDYL NITRILE COMPOUND AND USE THEREOF SHANGHAI YIDIAN PHARMACEUTICAL TECHNOLOGY DEVELOPMENT CO., LTD (CN) 2025-03-27 US disclosed
US-20090253688-A1 Semicarbazide derivatives as kinase inhibitors MERCK PATENT GMBH (DE) 2009-10-08 US disclosed
US-7589112-B2 Methylene urea derivatives MERCK PATENT GMBH (DE) 2009-09-15 US disclosed
US-20080318779-A1 N-[(4'-methoxy-2'-methyl-1,1-dimethyl)phenacyl]-3-methyl-2-thiophenecarboxamide and another fungicide or an antibiotic; controlling noxious fungi at a low dose; Oomycetes, Ascomycetes, Basidiomycetes, Deuteromycetes particularly effective against Ascomycetes or Deuteromycetes; plant diseases ISHIHARA SANGYO KAISHA LTD (JP) 2008-12-25 US disclosed
US-20070191423-A1 Isoquinoline derivatives MERCK PATENT GMBH (DE) 2007-08-16 US disclosed
US-20070191423-A1 Isoquinoline derivatives MERCK PATENT GMBH (DE) 2007-08-16 US disclosed
US-20070191444-A1 Benzimidazolyl derivatives MERCK PATENT GMBH (DE) 2007-08-16 US disclosed
US-20070191444-A1 Benzimidazolyl derivatives MERCK PATENT GMBH (DE) 2007-08-16 US disclosed
WO-2007026959-A2 DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZ0 [B] THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-03-08 WO disclosed
US-20070010537-A1 Fused pyramidine derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-01-11 US disclosed
EP-1657238-A1 FUSED PYRIMIDINE DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2006-05-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070191444-A1 Benzimidazolyl derivatives JAK1, MARK1, RAF1 KMT2A 2009/4885SMN1; SMN2 2417/4885MEN1 1171/4885
US-20250101011-A1 PEPTIDYL NITRILE COMPOUND AND USE THEREOF CTSC, CTSL, CTRL KMT2A 4482/4885SMN1; SMN2 1473/4885MEN1 2152/4885
US-20250109140-A1 5-[5-(PIPERIDIN-4-YL)THIENO[3,2-C]PYRAZOL-2-YL]INDAZOLE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR SPLICING NUCLEIC ACIDS AND FOR THE TREATMENT OF PROLIFERATIVE DISEASES SNRPA, HNRNPA3, HNRNPUL1 KMT2A 1796/4885SMN1; SMN2 372/4885MEN1 2840/4885
US-20070010537-A1 Fused pyramidine derivative and use thereof NR5A1, GNRHR, RXFP3 KMT2A 1132/4885SMN1; SMN2 2437/4885MEN1 1223/4885
US-20070191423-A1 Isoquinoline derivatives ABL1, MAP3K1, MAP3K2 KMT2A 1108/4885SMN1; SMN2 2588/4885MEN1 2006/4885
US-20260008780-A1 SUBSTITUTED 3,4-DIHYDROISOQUINOLIN-1(2H)-ONE DERIVATIVES AND RELATED USES NOD1, NLRP3, CASP1 KMT2A 3161/4885SMN1; SMN2 2237/4885MEN1 1374/4885
US-20090253688-A1 Semicarbazide derivatives as kinase inhibitors MAP3K1, MAP3K6, MAP3K2 KMT2A 912/4885SMN1; SMN2 3294/4885MEN1 1076/4885
US-20080318779-A1 N-[(4'-methoxy-2'-methyl-1,1-dimethyl)phenacyl]-3-methyl-2-thiophenecarboxamide and another fungicide or an antibiotic; controlling noxious fungi at a low dose; Oomycetes, Ascomycetes, Basidiomycetes, Deuteromycetes particularly effective against Ascomycetes or Deuteromycetes; plant diseases AADAC, NAT1, TH KMT2A 237/4885SMN1; SMN2 1332/4885MEN1 2049/4885
US-20260146037-A1 PEPTIDYL NITRILE COMPOUND AND USE THEREOF JAK1, CTSZ, CTSL KMT2A 1443/4885SMN1; SMN2 3667/4885MEN1 3993/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.